Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Cytokinetics (CYTK) Gross Profit: 2009-2025

Historic Gross Profit for Cytokinetics (CYTK) over the last 16 years, with Sep 2025 value amounting to $1.9 million.

  • Cytokinetics' Gross Profit rose 318.14% to $1.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $85.3 million, marking a year-over-year increase of 2549.39%. This contributed to the annual value of $15.0 million for FY2024, which is 99.20% up from last year.
  • Per Cytokinetics' latest filing, its Gross Profit stood at $1.9 million for Q3 2025, which was down 97.10% from $66.8 million recorded in Q2 2025.
  • Over the past 5 years, Cytokinetics' Gross Profit peaked at $89.0 million during Q2 2022, and registered a low of $249,000 during Q2 2024.
  • Over the past 3 years, Cytokinetics' median Gross Profit value was $1.6 million (recorded in 2025), while the average stood at $8.6 million.
  • As far as peak fluctuations go, Cytokinetics' Gross Profit slumped by 99.03% in 2023, and later surged by 26,714.86% in 2025.
  • Cytokinetics' Gross Profit (Quarterly) stood at $54.9 million in 2021, then plummeted by 96.43% to $2.0 million in 2022, then declined by 14.56% to $1.7 million in 2023, then surged by 797.13% to $15.0 million in 2024, then soared by 318.14% to $1.9 million in 2025.
  • Its Gross Profit was $1.9 million in Q3 2025, compared to $66.8 million in Q2 2025 and $1.6 million in Q1 2025.